Results of low- and high-dose-rate interstitial brachytherapy for T3 mobile tongue cancer
Results of low- and high-dose-rate interstitial brachytherapy for T3 mobile tongue cancer
复制标题
DOI：
10.1016/s0167-8140(03)00055-0
复制
发表时间：
2003-08-01
影响因子：
5.7
通讯作者：
Shimizutani, K
中科院分区：
文献类型：
--
作者：
Katimoto, N;Inoue, T;Shimizutani, K
目的：为评价低剂量率（LDR）和高剂量率（HDR）组织间近距离放射治疗（ISBT）治疗T3移动的舌癌的疗效，材料与方法：1974 ~ 1992年，对61例T3移动的舌癌患者进行了LDR ISBT治疗。此外，在1991年至1999年期间，14名患者接受了HDR ISBT治疗。对于9例单独接受ISBT治疗的患者，LDR ISBT组1周内的总剂量为59-94戈伊（中位数72戈伊），HDR ISBT组为60戈伊/10次/5天。66例采用外照射加ISBT治疗，总剂量12.5 ~ 60戈伊（中位数30戈伊）EBRT和50-112戈伊（中位数68戈伊）或32-60戈伊结果：本组患者2年、3年局部控制率均为68%，均为高剂量组（中位剂量48戈伊）/8-10次/5-7 d。LDR ISBT组2年和3年局部控制率均为67%，HDR ISBT组均为71%。结论：ISBT治疗T3期移动的舌癌是有效的，可接受的。HDR ISBT治疗T3期移动的舌癌的疗效与LDR ISBT相近。(C)2003爱思唯尔爱尔兰有限公司保留所有权利。
Purpose: To evaluate the treatment results of low-dose-rate (LDR) and high-dose-rate (HDR) interstitial brachytherapy (ISBT) for T3 mobile tongue cancer.Material and methods: Between 1974 and 1992, 61 patients with T3 mobile tongue cancer were treated with LDR ISBT using Ir-192 hairpins with or without single pins. In addition, between 1991 and 1999, 14 patients were treated with HDR ISBT. For nine patients treated with ISBT alone, the total dose was 59-94 Gy (median 72 Gy) within one week in LDR ISBT and 60 Gy/10 fractions/5 days in HDR ISBT. For 66 patients treated with a combination therapy of external beam radiotherapy (EBRT) and ISBT, the total dose was 12.5-60 Gy (median 30 Gy) of EBRT and 50-112 Gy (median 68 Gy) within 1 week in LDR ISBT or 32-60 Gy (median 48 Gy)/8-10 fractions/5-7 days in HDR ISBT.Results: The 2- and 3-year local control rates of all patients were both 68%. The 2- and 3-year local control rates of patients treated with LDR ISBT were both 67%, and those with HDR ISBT were both 71%. The local control rate of patients treated with HDR ISBT was similar to those with LDR ISBT.Conclusions: ISBT for T3 mobile tongue cancer is effective and acceptable. The treatment result of HDR ISBT is almost similar to that of LDR ISBT for T3 mobile tongue cancer. (C) 2003 Elsevier Ireland Ltd. All rights reserved.